AnorMED
Langley
About AnorMED
AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic drugs for the treatment of hematology, human immunodeficiency virus (HIV), and oncology. Its lead drug product candidate include MOZOBIL, which is under phase III clinical trial is used for cancer patients undergoing stem cell transplantation; and AMD070, which is under phase Ib/IIa trial is used as a HIV entry inhibitor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Website: anormed.com
- Phone: (604) 530-1057
Canonical: https://fsome.com/organization/anormed-2702095 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.